Product Data Sheet

7BIO

Cat. No.: HY-121035 CAS No.: 916440-85-2 Molecular Formula: $C_{16}H_{10}BrN_3O_2$

Molecular Weight: 356.17
Target: CDK; GSK-3

Pathway: Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Stem Cell/Wnt

Storage: 4°C, protect from light

* In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

SOLVENT & SOLUBILITY

In Vitro

DMSO: 250 mg/mL (701.91 mM; Need ultrasonic) Ethanol: 50 mg/mL (140.38 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.8076 mL	14.0382 mL	28.0765 mL
	5 mM	0.5615 mL	2.8076 mL	5.6153 mL
	10 mM	0.2808 mL	1.4038 mL	2.8076 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% EtOH >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (7.02 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (5.84 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

7BIO (7-Bromoindirubin-3-Oxime) is the derivate of indirubin. 7BIO (7-Bromoindirubin-3-Oxime) has inhibitory effects against cyclin-dependent kinase-5 (CDK5) and glycogen synthase kinase-3β (GSK3β). 7BIO (7-Bromoindirubin-3-Oxime) inhibits Aβ oligomer-induced neuroinflammation, synaptic impairments, tau hyper-phosphorylation, activation of astrocytes and microglia, and attenuates Aβ oligomer-induced cognitive impairments in mice^[1].

 IC_{50} & Target CDK5 GSK3 β

In Vitro 7BIO (1 and 10 μ M; 24 hours) has neuroprotective effects and can prevent, but cannot rescue A β 1–42 oligomer-induced cell death in SH-SY5Y cells^[1].

 $\label{eq:mce} \mbox{MCE has not independently confirmed the accuracy of these methods. They are for reference only.}$

Cell Viability Assay ^[1]		
Cell Line:	SH-SY5Y cells	
Concentration:	1 and 10 μM	
Incubation Time:	24 hours	
Result:	Inhibit Aβ oligomer-induced neuronal death. 7BIO prevented, but did not rescue Aβ1–42 oligomer-induced cell death in SH-SY5Y cells.	

In Vivo

7Bio (2.3, 7.0, and 23.3 μ g/kg; bilateral ventricle injection) significantly attenuates A β oligomer-induced impairment of recognition, spatial learning and memory in mice^[1].

7Bio (2.3, 7.0, and 23.3 μ g/kg; bilateral ventricle injection) decreases A β oligomer-induced increase of TNF- α and IL-6 production in the brain and the expression of synapsin-1 and PSD-95 in the hippocampal region of mice^[1].

7Bio (2.3, 7.0, and 23.3 μ g/kg; bilateral ventricle injection) attenuates A β oligomer-induced increase expression of pTau, activation of microglia and astrogliosis in the brain of mice^[1].

7Bio (2.3, 7.0, and 23.3 μ g/kg; bilateral ventricle injection) prevents decreased expression of pSer9-GSK3 β and has no significant effects on the Tau protein level^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	8 weeks mice (30 g) ^[1]	
Dosage:	2.3, 7.0, and 23.3 μg/kg	
Administration:	bilateral ventricle injection	
Result:	Attenuates $\mbox{A}\beta$ oligomer-induced impairment of recognition, spatial learning and memory in mice.	

REFERENCES

 $[1]. \ \ Chen\ L, et\ al.\ Indirubin\ Derivative\ 7-Bromoindirubin-3-Oxime\ (7Bio)\ Attenuates\ A\beta\ Oligomer-Induced\ Cognitive\ Impairments\ in\ Mice.\ Front\ Mol\ Neurosci.\ 2017;10:393.$

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA